BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26010519)

  • 1. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
    Verduzco D; Flaherty KT; Smalley KS
    Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
    Livingstone E; Swann S; Lilla C; Schadendorf D; Roesch A
    Exp Dermatol; 2015 Sep; 24(9):709-10. PubMed ID: 25865258
    [No Abstract]   [Full Text] [Related]  

  • 5. Overcoming metastatic melanoma with BRAF inhibitors.
    Hong S; Hong S; Han SB
    Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
    Smalley KSM; Forsyth PA
    Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 10. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 11. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
    Dummer R; Flaherty KT
    Curr Opin Oncol; 2012 Mar; 24(2):150-4. PubMed ID: 22316627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting BRAF in melanoma: biological and clinical challenges.
    MandalĂ  M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for single-agent BRAF inhibition in melanoma?
    Chmielowski B
    Clin Adv Hematol Oncol; 2017 Feb; 15(2):108-110. PubMed ID: 28398279
    [No Abstract]   [Full Text] [Related]  

  • 20. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.